E. Eriksson and F. Hieronymus, The alleged lack of efficacy of antidepressants in non-severe depression: a myth debunked, Acta Psychiatr Scand, vol.137, pp.447-449, 2018.

T. A. Furukawa, K. Maruo, and H. Noma, Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis, Acta Psychiatr Scand, vol.137, pp.450-458, 2018.

A. Cipriani, T. A. Furukawa, and G. Salanti, Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis, Lancet, vol.7, pp.1357-1366, 2018.

J. N. Jureidini, J. D. Amsterdam, and L. B. Mchenry, The citalopram CIT-MD-18 pediatric depression trial: deconstruction of medical ghostwriting, data mischaracterisation and academic malfeasance, Int J Risk Saf Med, vol.28, pp.33-43, 2016.

E. H. Turner, A. M. Matthews, E. Linardatos, R. A. Tell, and R. Rosenthal, Selective publication of antidepressant trials and its influence on apparent efficacy, N Engl J Med, vol.358, pp.252-260, 2008.

J. Moncrieff and I. Kirsch, Empirically derived criteria cast doubt on the clinical significance of antidepressant-placebo differences, Contemp Clin Trials, vol.43, pp.60-62, 2015.

S. Ebrahim, S. Bance, A. Athale, C. Malachowski, and J. P. Ioannidis, Meta-analyses with industry involvement are massively published and report no caveats for antidepressants, J Clin Epidemiol, vol.70, pp.155-163, 2016.

R. A. Friedman, Antidepressants' black-box warning-10 years later, N Engl J Med, vol.371, pp.1666-1668, 2014.

D. Healy and C. Whitaker, Antidepressants and suicide: risk-benefit conundrums, J Psychiatry Neurosci, vol.28, pp.331-337, 2003.

G. Catalano, M. C. Catalano, M. A. Epstein, and P. E. Tsambiras, QTc interval prolongation associated with citalopram overdose: a case report and literature review, Clin Neuropharmacol, vol.24, pp.158-162, 2001.

A. Ojero-senard, J. Benevent, and E. Bondon-guitton, A comparative study of QT prolongation with serotonin reuptake inhibitors, Psychopharmacology, vol.234, pp.3075-3081, 2017.

J. Wernicke, B. Pangallo, and F. Wang, Hepatic effects of duloxetine-I: non-clinical and clinical trial data, Curr Drug Saf, 2009.

, Curr Drug Saf, vol.3, pp.132-142, 2008.

, Silver Spring (MD): US Food and Drug Administration, US Food and Drug Administration, 2011.

. Prescrire, Towards better patient care: drugs to avoid in 2018, Prescrire Int, vol.27, pp.107-111, 2018.

H. Malm, M. Artama, M. Gissler, and A. Ritvanen, Selective serotonin reuptake inhibitors and risk for major congenital anomalies, Obstet Gynecol, vol.118, pp.111-120, 2011.

C. Ekhart, F. Van-hunsel, J. Scholl, S. De-vries, and E. Van-puijenbroek, Sex differences in reported adverse drug reactions of Selective Serotonin Reuptake Inhibitors, Drug Saf, vol.41, pp.677-683, 2018.

L. B. Finer and M. R. Zolna, Declines in unintended pregnancy in the United States, N Engl J Med, vol.374, pp.843-852, 2008.

M. Iglesias-gonz-alez, A. Gil-girbau, and M. , Comparing watchful waiting with antidepressants for the management of subclinical depression symptoms to mildmoderate depression in primary care: a systematic review, Fam Pract, vol.34, pp.639-648, 2017.

N. J. Wiles, L. Thomas, and N. Turner, Long-term effectiveness and cost-effectiveness of cognitive behavioural therapy as an adjunct to pharmacotherapy for treatmentresistant depression in primary care: follow-up of the CoBalT randomised controlled trial, Lancet Psychiatry, vol.3, pp.137-144, 2016.

D. A. Richards, D. Ekers, and D. Mcmillan, Cost and Outcome of Behavioural Activation versus Cognitive Behavioural Therapy for Depression (COBRA): a randomised, controlled, non-inferiority trial, Lancet, vol.388, pp.871-880, 2016.

R. K. Mchugh, S. W. Whitton, A. D. Peckham, J. A. Welge, and M. W. Otto, Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review, J Clin Psychiatry, vol.7, pp.595-602, 2013.

S. Kolovos, A. Kleiboer, and P. Cuijpers, Effect of psychotherapy for depression on quality of life: meta-analysis, Br J Psychiatry, vol.209, pp.460-468, 2016.

G. R. Cox, P. Callahan, and R. Churchill, Psychological therapies versus antidepressant medication, alone and in combination for depression in children and adolescents, Cochrane Database Syst Rev, issue.11, p.8324, 2014.

H. R. Amick, G. Gartlehner, and B. N. Gaynes, Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and metaanalysis, BMJ, vol.351, p.6019, 2015.

M. E. Thase, E. S. Friedman, and M. M. Biggs, Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report, Am J Psychiatry, vol.164, pp.739-752, 2007.

S. V. Parikh, L. C. Quilty, and P. Ravitz, Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: section 2. Psychological treatments, Can J Psychiatry, vol.61, pp.524-539, 2016.